company background image
P09 logo

Pacific Biosciences of California DB:P09 Stock Report

Last Price

€1.54

Market Cap

€462.4m

7D

-16.9%

1Y

-79.5%

Updated

22 Nov, 2024

Data

Company Financials +

Pacific Biosciences of California, Inc.

DB:P09 Stock Report

Market Cap: €462.4m

Pacific Biosciences of California, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pacific Biosciences of California
Historical stock prices
Current Share PriceUS$1.54
52 Week HighUS$9.40
52 Week LowUS$1.05
Beta2.01
11 Month Change-3.59%
3 Month Change22.86%
1 Year Change-79.51%
33 Year Change-92.48%
5 Year Change-66.32%
Change since IPO-87.15%

Recent News & Updates

Recent updates

Shareholder Returns

P09DE Life SciencesDE Market
7D-16.9%-6.1%-1.3%
1Y-79.5%2.0%7.4%

Return vs Industry: P09 underperformed the German Life Sciences industry which returned 2% over the past year.

Return vs Market: P09 underperformed the German Market which returned 7.4% over the past year.

Price Volatility

Is P09's price volatile compared to industry and market?
P09 volatility
P09 Average Weekly Movement19.1%
Life Sciences Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.8%
10% least volatile stocks in DE Market2.4%

Stable Share Price: P09's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: P09's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2000796Christian O. Henrywww.pacb.com

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.

Pacific Biosciences of California, Inc. Fundamentals Summary

How do Pacific Biosciences of California's earnings and revenue compare to its market cap?
P09 fundamental statistics
Market cap€462.44m
Earnings (TTM)-€376.10m
Revenue (TTM)€165.18m

2.8x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
P09 income statement (TTM)
RevenueUS$173.15m
Cost of RevenueUS$118.91m
Gross ProfitUS$54.23m
Other ExpensesUS$448.47m
Earnings-US$394.24m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.44
Gross Margin31.32%
Net Profit Margin-227.69%
Debt/Equity Ratio197.1%

How did P09 perform over the long term?

See historical performance and comparison